Research programme: anticancer antibodies - Agensys

Drug Profile

Research programme: anticancer antibodies - Agensys

Alternative Names: AGS-15 MAb; AGS-16 MAb; AGS-22 MAb; AGS-23 MAb; AGS-3 MAb; AGS-33 MAb; AGS-5 MAb; AGS-8 MAb

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agensys
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
  • 30 Mar 2010 Preclinical development is ongoing in USA
  • 16 Jun 2008 Pharmacodynamics data from a preclinical study presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top